Allergy Therapeutics completes treatment phase in innovative G309 exploratory field study

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the completion of treatment period of all patients in its exploratory field study (G309) to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen. Grass MATA MPL is a short course, aluminium-free allergen-specific subcutaneous immunotherapy (SCIT) that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Completion of the treatment phase of the study has been achieved despite the challenges caused by the continuing COVID-19 pandemic. The Group has executed the dosing phase of the study in such a way that high patient retention has been achieved (97%) without any delay to the scheduled read-out of the data. The G309 double-blind, placebo controlled, randomised study, performed simultaneously in the USA and EU, remains on track to read out in H2 2021.

Grass pollen is one of the most common causes of seasonal allergic rhinitis in the Western world1. The symptoms caused by allergic rhinitis reduce patients’ quality of life as well as performance at work or school.  The World Allergy Organization estimates that the prevalence of allergic rhinitis in the whole population ranges between 10 – 30%2.

The primary objective of the study is to evaluate the safety and efficacy of a dose of 27,600 SU Grass MATA MPL, previously proven as the optimal efficacious dose in the successful Phase II dose-finding study (G205). The study is being conducted in patients with grass pollen induced rhinoconjunctivitis and the primary endpoint is the combined symptom medication score (CSMS) averaged over the peak grass pollen season.

Results from the G309 study will provide valuable information to optimise the study design of the pivotal Phase III study (G306). The G309 study will inform the sample size of the G306 study which is expected to involve approximately 900-1200 patients over more than 100 trial sites in the EU and USA. Successful completion of the trial is expected to enable the Group to register the Grass MATA MPL product under the TAV (Therapy Allergy Ordinance) process in Germany and should also pave the way forward for registration via a Biological License Application (BLA) in the USA.

Manuel Llobet, CEO at Allergy Therapeutics, stated: “This ground-breaking exploratory trial design has the potential to greatly increase our understanding of allergic rhinitis and how to effectively generate data for product registration via field trials. Challenges brought about by COVID-19 were alleviated by the excellent clinical team here at Allergy Therapeutics and we are very much looking forward to the results later this year. The results of the G309 trial will enable us to optimise the design of the pivotal trial G306, which we expect to begin in H2 2022.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million